Document is current
Any future updates will be listed below
-
Authors
Vierke, Christopher
Marxen, Brigitte
Boettcher, Michael
Hiemke, Christoph
Havemann-Reinecke, Ursula
- License Information
-
More Information
Article History
Received: 22 July 2019
Accepted: 11 December 2019
First Online: 6 January 2020
Compliance with ethical standards
:
: Christoph Hiemke has received speaker’s or consultancy fees from the following pharmaceutical companies: Janssen-Cilag, Otsuka, Lohmann Transdermale Systeme, Roche and Servier. He is the managing editor of PSIAC (ExternalRef removed) which provides an internet-based drug–drug interaction program for psychopharmacotherapy. He reports no conflict of interest with this publication. Ursula Havemann-Reinecke has served on the advisory Board on opioid maintenance treatment of Sanofi and Indivior London. She has received speaker’s fee from Hexal. She reports no conflict of interest with this publication. Michael Böttcher and Christopher Vierke report no conflicts of interests.
